Celsion (CLSN) Spikes On Positive Interim Data from its Phase 2 DIGNITY Study

Celsion Corp. (CLSN) shares are surging by nearly 21% to $3.21 after the company announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in recurrent chest wall (RCW) breast cancer. Dr. Nicholas Borys, Celsion’s Senior Vice President and Chief Medical Officer said in a statement, “The objective tumor response […] View the full post at: Celsion (CLSN) Spikes On Positive Interim Data from its Phase 2 DIGNITY Study Related posts: Economic Data for the Week of Sept. 8 – 11 Economic Data: CPI Higher than Expected